ANKRD1 and cardiac hypertrophy: Four weeks later, olmesartan significantly reduced the TAC-induced cardiac hypertrophy (Fig. 6C), and the HW/BW ratio in olmesartan-treated TAC mice was significantly smaller than in vehicle-treated TAC group, while addition of Ad-Ankrd1 partially blocked the antihypertrophic effect of olmesartan (P<0.05 or 0.01, Fig. 6D).